GlassScriptPhysician profile
Sue Adams
NPI 1598734170
$3,809.67
in general payments reported to CMS, 2019-2025
23 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $725 · 2021: $373 · 2022: $317 · 2023: $451 · 2024: $490 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,256.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $756.67 | 2019-2025 | |
| Abbvie INC. | $482.73 | 2020-2025 | Mavyret |
| Novo Nordisk INC | $349.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $259.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $179.31 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $73.12 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $70.28 | 2019-2020 | |
| Dexcom, INC. | $55.99 | 2021-2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $52.15 | 2020 | |
| Sanofi Pasteur INC. | $39.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.55 | 2019-2020 | |
| Amarin Pharma, INC. | $28.93 | 2020 | |
| Shire North American Group INC | $26.59 | 2019 | |
| Seqirus USA INC | $21.37 | 2025 | Flucelvax, Fluad |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.63 | 2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $19.38 | 2020 | |
| Mylan Specialty L.P. | $16.25 | 2019 | |
| Amgen INC. | $13.92 | 2020 | |
| Gilead Sciences, INC. | $13.61 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.75 | 2019 | |
| Glaxosmithkline, LLC. | $11.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.